STOCK TITAN

Exact Sciences Corp - EXAS STOCK NEWS

Welcome to our dedicated page for Exact Sciences news (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences stock.

Exact Sciences Corporation (EXAS) delivers innovative cancer diagnostics through products like Cologuard® and Oncotype DX®. This page provides investors and healthcare professionals with essential updates on the company’s advancements in early cancer detection.

Find curated press releases and news covering financial results, regulatory milestones, product innovations, and strategic partnerships. Our repository ensures timely access to developments impacting precision oncology and noninvasive screening technologies.

Stay informed about EXAS’ role in molecular diagnostics, including updates on clinical studies, technology licensing agreements, and market expansion efforts. All content is verified for accuracy and relevance to support informed decision-making.

Bookmark this page for streamlined access to Exact Sciences’ latest developments. Check back regularly for authoritative updates directly affecting the future of cancer screening and diagnostic solutions.

Rhea-AI Summary
Exact Sciences Corp. collaborates with Mayo Clinic to develop a non-endoscopic screening tool for esophageal adenocarcinoma and its precursors, showing high sensitivity and specificity in detecting early stages of the cancer. The test aims to address the critical need for screening in high-risk populations, with potential to revolutionize esophageal cancer detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.26%
Tags
none
-
Rhea-AI Summary
Exact Sciences Corp. (EXAS) receives the 2024 Gallup Exceptional Workplace Award for its engaged workplace culture, highlighting dedication to teamwork, well-being, and professional growth. The company's employee engagement ratio surpasses global averages, emphasizing its commitment to eradicating cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.51%
Tags
none
-
Rhea-AI Summary
Exact Sciences Corp. announces the online publication of the BLUE-C study results in The New England Journal of Medicine, showcasing the performance of their next-generation multitarget stool DNA test, Cologuard Plus, for colorectal cancer screening. The study demonstrated 94% sensitivity for CRC at 91% specificity, outperforming the fecal immunochemical test. Cologuard Plus aims to reduce unnecessary follow-up colonoscopies and is set to be available in 2025 pending FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
none
Rhea-AI Summary
Exact Sciences Corp. collaborates with The Blue Hat Foundation to launch 'Box Out Colon Cancer' campaign with Jamal Mashburn, promoting colorectal cancer screening and prevention during Colorectal Cancer Awareness Month.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.22%
Tags
none
-
Rhea-AI Summary
Exact Sciences Corp. (EXAS) to participate in TD Cowen 44th Annual Health Care Conference with a fireside chat on March 4, 2024. Investors invited to join via webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
conferences
-
Rhea-AI Summary
Exact Sciences Corp. reports record revenue, positive free cash flow, and expects 2024 revenue of $2.810-2.850 billion. The fourth quarter and 2023 highlights include total revenue of $647 million, a 17% increase, with Screening revenue at $487 million and Precision Oncology revenue at $160 million. The company's financial results showcase growth in both revenue and cash flow, reflecting a strong performance in cancer screening and diagnostic tests.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6%
Tags
Rhea-AI Summary
Exact Sciences Corp. (Nasdaq: EXAS) plans to release its fourth quarter 2023 financial results on February 21, 2024, followed by a webcast and conference call to discuss financial results and business progress. The webcast and call will be open to all interested parties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.25%
Tags
-
Rhea-AI Summary
Exact Sciences Corp. (Nasdaq: EXAS) anticipates record fourth-quarter revenue, expects full-year 2024 revenue of $2.83 billion, and submits next-generation Cologuard to FDA. The company also announces Chief Financial Officer succession plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.59%
Tags
-
Rhea-AI Summary
Exact Sciences Corp. (Nasdaq: EXAS) will participate in the J.P. Morgan Healthcare Conference on January 8, 2024, at 2:15 p.m. ET, with a webcast available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
conferences
Rhea-AI Summary
Exact Sciences (EXAS) awarded $1.3 million to 23 organizations through its FOCUS Program to improve colorectal cancer screening rates. Since 2022, the program has awarded $2.9 million to 50 organizations. The company developed Cologuard, the first FDA-approved noninvasive screening test, and has delivered over 13 million results since 2014.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none
Exact Sciences Corp

Nasdaq:EXAS

EXAS Rankings

EXAS Stock Data

8.22B
183.06M
1.07%
100.78%
5.74%
Diagnostics & Research
Services-medical Laboratories
Link
United States
MADISON